Company Overview of SK Capital Partners
SK Capital Partners is a private equity firm specializing in investing in recapitalizations, industry consolidation, businesses in transition, growth equity investments, corporate spinouts, corporate carveouts, multinational companies, partnerships with family-owned businesses or entrepreneurs, and control buyouts in mature and middle market companies. It seeks to invest in specialty material and chemicals, healthcare, supply chain and logistics, aerospace and defence, and information and technology sectors. Within specialty material and chemicals, the firm seeks to invest in personal care ingredients, nutrition and food ingredients, flavors and fragrances, agrochemicals, plastics, composite...
400 Park Avenue
New York, NY 10022
Founded in 2007
Key Executives for SK Capital Partners
Co-Founder, President, and Managing Director
Co-Founder, Founding Partner, and Managing Director
Operating Partner and General Counsel
Compensation as of Fiscal Year 2016.
SK Capital Partners Key Developments
SK Capital Announces Executive Changes
Jul 20 16
SK Capital announced a new organizational structure and additions to the senior management team of the firm’s recently acquired Noramco Inc. and Tasmanian Alkaloids. Matthew Martin, who was previously the General Manager for the recently acquired businesses has been appointed CEO. Mr. Martin will be supported by a management team comprised of senior executives that are transitioning with the businesses as well as an influx of new, highly-experienced talent. Jim Mish, President, Noramco. Chris Close, Chief Financial Officer. Charlie Enzinger, Vice President, Integrated Supply Chain, Noramco. Chris Close joins from Preferred Proppants where he held the position of Chief Financial Officer. He brings significant financial leadership and experience in chemicals, energy and distribution with a broad based financial background that encompasses FP&A, investor relations, M&A, treasury, financial reporting and accounting. Mr. Close started his career in public accounting with PricewaterhouseCoopers before progressing into industry where he has operated in both corporate and business unit roles at companies such as ARCO Chemical, Airgas, Exelon Corporation and Constellation Energy. Charlie Enzinger joins the team from Univar, where he was responsible for leading the company’s supply chain transformation initiatives. Throughout his career, he has held executive roles at leading industrial and specialty chemical companies, including Nalco and DuPont where he specialized in leading turnaround initiatives such as improving underperforming supply chain and plant operations. Jim Mish spent over 30 years in the specialty chemical industry in executive leadership positions at both privately-held and publicly-traded companies. He joins the team from Ashland where he held the role of President of Global Consumer Specialties. Previously, he served as Senior Vice President of Personal Care and Pharmaceutical Ingredients at International Specialty Products (ISP), which was acquired by Ashland in 2011.
SK Capital Partners Announces the Promotion of Three of its Investment Professionals
Jun 28 16
SK Capital Partners noted that Stephen d'Incelli has been promoted to Principal after joining the company as a Vice President in 2015. Prior to the company, d'Incelli was a Vice President at Sun Capital Partners for eight years where he led a variety of portfolio activities including divestitures, asset sales, debt refinancing and recapitalizations, and had active board-level responsibilities for several of Sun Capital's portfolio companies across the diversified industrials, healthcare and consumer retail sectors. The firm also announced the promotion of Jay Taunk, who joined the firm in 2015, to Senior Associate. He previously worked at Vestar Capital Partners, where he focused on leveraged buyout transactions across multiple industries, and in the Healthcare Group of Morgan Stanley.
SK Capital Eyeing Tasmanian Alkaloids
Mar 10 16
SK Capital Partners may acquire Tasmanian Alkaloids Pty Ltd. (TA). The company looks set to be sold to SK Capital. On March 9, 2016, TA's staff was told that SK Capital was taking over a potential deal to be finalized in June 2016. Johnson & Johnson (NYSE:JNJ) said that it would not comment until the sale was complete, Tasmania Alkaloids said their expectation was ‘business as usual’. Tasmania Alkaloids Chief Executive Officer, Keith Rice said he was keen to meet SK Capital's representatives when they visited in April 2016. Keith Rice said, “It is a private investment firm with a focus on specialty materials, chemicals and healthcare. Its portfolio of companies generates revenues of over $8 billion annually, and it employs 9,000 people. We've not found out a great deal about it and I imagine its footprint goes beyond the United States. We understand that representatives of the company will be out here in the not too distant future, and naturally, we will be looking forward to meeting with them and seeing what their plans are for the future of the industry in Tasmania.”
Similar Private Companies By Industry
Recent Private Companies Transactions